Nightingale Health expands biomarker services and Bioanalysis Zone features new article from Bioanalysis
Proposal for risk-based scientific approach on full and partial validation for general changes in bioanalytical method
Georgi Makin (Future Science Group)
Bioanalysis Zone has released a new research article from Bioanalysis 10(8) entitled, ‘Proposal for risk-based scientific approach on full and partial validation for general changes in bioanalytical method’. The article will be free to view for Bioanalysis Zone members, and “presents perspectives and recommendations for most conceivable changes that can be made to full and partial validations by members of the discussion groups based on their experiences and discussions at the Japan Bioanalysis Forum Symposium.”
You can find out more, here.
♦
Nightingale Health announces plan to expand biomarker services to include urine, cerebrospinal fluid and cord blood analysis
Rhiannon Finnie (Future Science Group)
Nightingale Health (Helsinki, Finland), innovator of an internationally recognized blood biomarker testing technology, has recently announced plans to expand and further develop its services. Nightingale now intends to include services to analyze urine, cerebrospinal fluid and umbilical cord blood samples.
Nightingale’s current blood biomarker analysis service is built upon an unrivalled scientific foundation, with over 100 peer-reviewed publications in leading biomedical journals. As well as their current focus on cardiovascular disease and diabetes research, the company will now be able to cater for research into neurodegenerative conditions, kidney diseases and maternal and fetal health.
Teemu Suna, CEO and Founder of Nightingale Health, explained: “We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease.”
The company is currently taking advanced orders from research institutions worldwide, and the first results from the expanded services are expected to be delivered in Autumn 2018.
Janna Ranta, Head of Business, Products and Services at Nightingale Health, concluded: “We’re extremely proud to launch these new services, supporting molecular discoveries via biomarker profiling in cohorts and clinical trials. Nightingale’s novel services utilize high-throughput NMR-based technology, providing cost-effective and scalable solutions. These latest advances will provide new opportunities to researchers for biomarker discovery and translational impact.”
Source: www.eurekalert.org/pub_releases/2018-05/nh-nhe051418.php
